
Conxita Jacobs-Cacha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8387026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. Journal of the American Society of Nephrology: JASN, 2020, 31, 1380-1383.	3.0	453
2	Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme: Implications for Albuminuria in Diabetes. Journal of the American Society of Nephrology: JASN, 2006, 17, 3067-3075.	3.0	439
3	ACE and ACE2 Activity in Diabetic Mice. Diabetes, 2006, 55, 2132-2139.	0.3	270
4	Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. International Journal of Molecular Sciences, 2017, 18, 563.	1.8	215
5	Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. American Journal of Physiology - Renal Physiology, 2009, 296, F398-F405.	1.3	188
6	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). Nephrology Dialysis Transplantation, 2015, 30, ii1-ii142.	0.4	113
7	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
8	ADAM17 inhibition may exert a protective effect on COVID-19. Nephrology Dialysis Transplantation, 2020, 35, 1071-1072.	0.4	98
9	Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1941-1943.	3.0	95
10	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney International, 2021, 100, 196-205.	2.6	95
11	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, 2020, 9, 947.	1.0	85
12	Sex hormones and their influence on chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 1-9.	1.0	74
13	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	2.2	74
14	Pharmacologic modulation of ACE2 expression. Current Hypertension Reports, 2008, 10, 410-4.	1.5	69
15	SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. CKJ: Clinical Kidney Journal, 2020, 13, 728-733.	1.4	68
16	Matrix Metalloproteinases in Diabetic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 472.	1.0	65
17	New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy. Experimental Diabetes Research, 2012, 2012, 1-9.	3.8	62
18	Coronavirus disease 2019 in chronic kidney disease. CKI: Clinical Kidney Journal. 2020. 13. 297-306	14	59

CONXITA JACOBS-CACHA

#	Article	IF	CITATIONS
19	Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. American Journal of Physiology - Renal Physiology, 2016, 310, F534-F546.	1.3	51
20	Revisiting Experimental Models of Diabetic Nephropathy. International Journal of Molecular Sciences, 2020, 21, 3587.	1.8	46
21	Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse. PLoS ONE, 2014, 9, e84683.	1.1	45
22	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrology Dialysis Transplantation, 2022, 37, 1868-1878.	0.4	43
23	Endothelin Blockade in Diabetic Kidney Disease. Journal of Clinical Medicine, 2015, 4, 1171-1192.	1.0	39
24	Angiotensin onverting enzyme 2 and the kidney. Experimental Physiology, 2008, 93, 549-556.	0.9	38
25	Mild cognitive impairment and kidney disease: clinical aspects. Nephrology Dialysis Transplantation, 2020, 35, 10-17.	0.4	38
26	Impact of Recurrent Acute Kidney Injury on Patient Outcomes. Kidney and Blood Pressure Research, 2018, 43, 34-44.	0.9	37
27	Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy. Laboratory Investigation, 2018, 98, 1237-1249.	1.7	36
28	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. CKJ: Clinical Kidney Journal, 2019, 12, 313-321.	1.4	35
29	Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney International, 2021, 99, 227-237.	2.6	33
30	A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management. Frontiers in Medicine, 2021, 8, 655871.	1.2	32
31	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. CKJ: Clinical Kidney Journal, 2021, 14, 1364-1370.	1.4	30
32	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. Journal of Clinical Medicine, 2020, 9, 2030.	1.0	28
33	Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. Nephrology Dialysis Transplantation, 2019, 34, 1112-1114.	0.4	27
34	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1833-1839.	2.2	27
35	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, i13-i23.	0.4	26
36	MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. Scientific Reports, 2020, 10, 26.	1.6	24

CONXITA JACOBS-CACHA

#	Article	IF	CITATIONS
37	Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 872-876.	2.2	24
38	Sodium-glucose cotransporter inhibitors: beyond glycaemic control. CKJ: Clinical Kidney Journal, 2019, 12, 322-325.	1.4	23
39	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, , .	0.4	23
40	Circulating Endothelial Progenitor Cells After Kidney Transplantation. American Journal of Transplantation, 2005, 5, 2154-2159.	2.6	22
41	Apolipoprotein A-lb as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. Transplant International, 2019, 32, 313-322.	0.8	22
42	A pharmacologically-based array to identify targets of cyclosporine A-induced toxicity in cultured renal proximal tubule cells. Toxicology and Applied Pharmacology, 2012, 258, 275-287.	1.3	19
43	Gonadectomy prevents the increase in blood pressure and glomerular injury in angiotensin-converting enzyme 2 knockout diabetic male mice. Effects on renin–angiotensin system. Journal of Hypertension, 2016, 34, 1752-1765.	0.3	19
44	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. PLoS Pathogens, 2022, 18, e1010171.	2.1	18
45	The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. Journal of Clinical Medicine, 2019, 8, 864.	1.0	17
46	How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR. Journal of Clinical Medicine, 2021, 10, 2505.	1.0	17
47	Impacto de la pandemia COVID-19 en los servicios de NefrologÃa españoles. Nefrologia, 2020, 40, 579-584.	0.2	16
48	Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules, 2022, 12, 143.	1.8	16
49	Diabetes and renal disease—should we biopsy?. Nephrology Dialysis Transplantation, 2021, 36, 1384-1386.	0.4	15
50	Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.4	14
51	Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. Nephrology Dialysis Transplantation, 2022, 37, 994-999.	0.4	14
52	Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice. CKJ: Clinical Kidney Journal, 2022, 15, 1593-1600.	1.4	14
53	Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease. Molecular and Cellular Proteomics, 2017, 16, 368-385.	2.5	13
54	Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?. CKJ: Clinical Kidney Journal, 2021, 14, 884-890.	1.4	13

#	ARTICLE	IF	CITATIONS
55	A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas mice with proliferative lupus nephritis predicts low effect size. Kidney International, 2021, 99, 1331-1341.	2.6	13
56	Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. CKJ: Clinical Kidney Journal, 2021, 14, 482-491.	1.4	12
57	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	1.4	11
58	Nephrology: achieving sustainability. Nephrology Dialysis Transplantation, 2020, 35, 2030-2033.	0.4	10
59	A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis. Scientific Reports, 2020, 10, 1159.	1.6	10
60	A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, 23-35.	1.4	10
61	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. Kidney360, 2022, 3, 293-306.	0.9	10
62	Diabetes, Albuminuria and the Kidney—Brain Axis. Journal of Clinical Medicine, 2021, 10, 2364.	1.0	9
63	SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?. Nephrology Dialysis Transplantation, 2021, 36, 1950-1954.	0.4	9
64	Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2020, 35, 130-138.	0.4	8
65	Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe. Nephrology Dialysis Transplantation, 2019, 34, 1469-1480.	0.4	8
66	Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy. CKJ: Clinical Kidney Journal, 2019, 12, 33-35.	1.4	8
67	Optimizing the timing of nephrology referral for patients with diabetic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 5-8.	1.4	8
68	The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19. Journal of Clinical Medicine, 2021, 10, 3022.	1.0	8
69	Renin-Angiotensin System Blockers and the Risk of COVID-19–Related Mortality in Patients with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1061-1072.	2.2	7
70	Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model. Molecular and Cellular Endocrinology, 2021, 529, 111263.	1.6	7
71	New aspects in cardiorenal syndrome and HFpEF. CKJ: Clinical Kidney Journal, 2022, 15, 1807-1815.	1.4	7

Ageing meets kidney disease. Age and Ageing, 2022, 51, .

0.7 7

#	Article	IF	CITATIONS
73	Funding kidney research as a public health priority: challenges and opportunities. Nephrology Dialysis Transplantation, 2020, , .	0.4	6
74	Haematological disorders following kidney transplantation. Nephrology Dialysis Transplantation, 2022, 37, 409-420.	0.4	6
75	Association of renin–angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension: a population-based study. CKJ: Clinical Kidney Journal, 0, , .	1.4	6
76	The COVID-19 pandemic: progress in nephrology. Nature Reviews Nephrology, 2022, 18, 80-81.	4.1	6
77	Ageing meets kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 1793-1796.	1.4	6
78	Single-cell RNA profiling of glomerular cells in diabetic kidney: a step forward for understanding diabetic nephropathy. Annals of Translational Medicine, 2019, 7, S340-S340.	0.7	5
79	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. Journal of the American Society of Nephrology: JASN, 2022, 33, 1223-1224.	3.0	5
80	<i>Lancet</i> Countdown paper: what does it mean for nephrology?. Nephrology Dialysis Transplantation, 2019, 34, 4-6.	0.4	4
81	SGLT2i and postglomerular vasodilation. Kidney International, 2020, 97, 805-806.	2.6	4
82	COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?. CKJ: Clinical Kidney Journal, 2022, 15, 1698-1704.	1.4	4
83	Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes. International Journal of Molecular Sciences, 2021, 22, 13093.	1.8	4
84	Should high molecular weight forms of apolipoprotein A-I be analyzed in urine of relapsing FSGS patients?. Pediatric Nephrology, 2019, 34, 2423-2424.	0.9	3
85	Biopsia renal transyugular. La alternativa a la biopsia percutánea en pacientes de alto riesgo. Nefrologia, 2020, 40, 634-639.	0.2	3
86	Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria. International Journal of Molecular Sciences, 2020, 21, 2245.	1.8	3
87	Tweet me: conferencing in the era of COVID-19 and 280 characters. CKJ: Clinical Kidney Journal, 2021, 14, 2142-2150.	1.4	3
88	COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab. Nefrologia, 2021, 41, 354-355.	0.2	3
89	Revisiting the renin-angiotensin system. Molecular and Cellular Endocrinology, 2021, 529, 111268.	1.6	3
90	Fascin-1 is released from proximal tubular cells in response to calcineurin inhibitors (CNIs) and correlates with isometric vacuolization in kidney transplanted patients. American Journal of Translational Research (discontinued), 2017, 9, 4173-4183.	0.0	3

CONXITA JACOBS-CACHA

#	Article	IF	CITATIONS
91	A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2174.	1.0	2
92	COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease. Kidney and Blood Pressure Research, 2021, 46, 452-459.	0.9	2
93	Endothelial ADAM17 Expression in the Progression of Kidney Injury in an Obese Mouse Model of Pre-Diabetes. International Journal of Molecular Sciences, 2022, 23, 221.	1.8	2
94	Ageing meets kidney disease. Nephrology Dialysis Transplantation, 0, , .	0.4	2
95	Is There Decreasing Public Interest in Renal Transplantation? A Google TrendsTM Analysis. Journal of Clinical Medicine, 2020, 9, 1048.	1.0	1
96	COVID-19 and its impact on the kidney and the nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, i1-i5.	1.4	1
97	Exploring Renal Changes after Bariatric Surgery in Patients with Severe Obesity. Journal of Clinical Medicine, 2022, 11, 728.	1.0	1
98	Crying kidneys: Bilateral renal contrast leak. Journal of Onco-Nephrology, 2019, 3, 171-173.	0.3	0
99	P134â€A preclinical double-blinded, randomized, controlled, multicenter trial (pRCT) on Jak1/Jak2 inhibition in lupus nephritis. , 2020, , .		0
100	P0196ACUTE TUBULOINTERSTITIAL NEPHRITIS (ATIN) INDUCED BY CHECKPOINT INHIBITORS (ICI) VERSUS CLASSICAL ATIN. ARE THEY THE SAME DISEASE?. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
101	Authors' Reply. Journal of the American Society of Nephrology: JASN, 2020, 31, 1918-1919.	3.0	0
102	FC 026COVID-19 IMPACT ON ELDERLY HEMODIALYSIS POPULATION: RESULTS FROM THE SPANISH COVID-19 CKD WORKING GROUP REGISTRY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
103	FC 088DUAL BLOCKADE OF ENDOTHELIN A RECEPTOR (ETA) AND SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) TO PREVENT DIABETIC KIDNEY DISEASE PROGRESSION ON A TYPE 2 MURINE MODEL. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0